Patients with the KRAS mutation p.G12C in their pancreatic tumor have now the opportunity to get specific p.G12C inhibitors (sotorasib and adagrasib), which are FDA approved for non-small cell lung cancer and have shown promising results for pancreatic cancer [32, 33]. Here, KRAS is linked to pancreatic neoplasm.